Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Sep;89(9):933-9.
doi: 10.1111/j.1349-7006.1998.tb00651.x.

Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm

H Konno  1 , T Arai, T Tanaka, M Baba, K Matsumoto, T Kanai, S Nakamura, S Baba, Y Naito, H Sugimura, A Yukita, M Asano, H Suzuki
Affiliations

Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm

H Konno et al. Jpn J Cancer Res. 1998 Sep.

Abstract

Distant metastasis of gastrointestinal endocrine neoplasm is resistant to currently available treatments. Because hematogenic metastasis is dominant, anti-angiogenic drugs are expected to be a novel therapy for this neoplasm. In the present study, the therapeutic effect of vascular endothelial growth factor neutralizing antibody (VEGFAb) on liver metastasis of an endocrine neoplasm was investigated experimentally. Cecal transplantation into nude mice of small pieces of EN-1, a xenotransplanted human intestinal endocrine neoplasm, resulted in liver metastasis. A treated group (n = 19) received 100 micrograms/mouse of VEGFAb intraperitoneally on alternate days from day 10 after tumor transplantation, and the control group (n = 19) received saline. Five of the 19 control mice died of tumor progression, of which 2 could not be evaluated. The cecal tumor weighed 6316 +/- 2333 mg (n = 17) in the control group and 1209 +/- 837 mg (n = 19) in the treated group (P < 0.01) 6 weeks after transplantation. Liver metastasis developed in 16 of 17 control mice and in 2 of 19 treated mice (P < 0.01). The VEGF level of the whole cecal tumor in the control group was significantly higher than that in the treated group (305.1 +/- 174.1 vs. 54.7 +/- 41.2 mg; P < 0.001). VEGFAb did not cause any body weight loss (28.52 +/- 1.63 in the control vs. 28.44 +/- 1.71 g in the treated group). These results indicate that VEGFAb may be a novel therapeutic agent for endocrine neoplasm with distant metastasis.

PubMed Disclaimer

References

    1. ) Creutzfeldt , W. and Stockmann , F.Carcinoids and carcinoid syndrome . Am. J. Med. , 82 , 4 – 16 ( 1987. ). - PubMed
    1. ) Bruine , A. P. , Diejens , W. N. M. , Pijls , M. M. J. , Linden , E. P. M. v.d. , Rousch , M. J. M. , Moerkerk , P. T. , de Goeij , A. F. P. M. and Bosman , F. T.NCI‐H716 cells as a model for endocrine differentiation in colorectal cancer . Virchows Arch. B Cell Pathol. , 62 , 311 – 320 ( 1992. ). - PubMed
    1. ) Oberg , K.Endocrine tumors of the gastrointestinal tract: systemic treatment . Anticancer Drugs , 5 , 503 – 519 ( 1994. ). - PubMed
    1. ) Tanaka , T. , Konno , H. , Matsuda , I. , Nakamura , S. and Baba , S.Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP‐470 . Cancer Res. , 55 , 836 – 839 ( 1995. ). - PubMed
    1. ) Konno , H. , Tanaka , T. , Kanai , T. , Maruyama , K. , Nakamura , S. and Baba , S.Efficacy of an angiogenesis inhibitor, TNP‐470, in xenotransplanted human colorectal cancer with high metastatic potential . Cancer , 77 , 1736 – 1740 ( 1996. ). - PubMed

MeSH terms

Substances